Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis. Novel role for an old enemy.
AuthorsCoffey, J Calvin
Wang, Jiang Huai
Smith, Myles J F
Cotter, Tom G
Redmond, H Paul
AffiliationDepartment of Surgery, Cork University Hospital, Wilton, Cork, Munster, Ireland. , firstname.lastname@example.org
Apoptosis Regulatory Proteins
*Drug Resistance, Neoplasm
*Gene Expression Regulation, Neoplastic
In Situ Nick-End Labeling
Oligonucleotide Array Sequence Analysis
TNF-Related Apoptosis-Inducing Ligand
Tumor Necrosis Factor-alpha/metabolism
MetadataShow full item record
CitationJ Biol Chem. 2005 Jun 3;280(22):20968-77. Epub 2005 Mar 1.
JournalThe Journal of biological chemistry
AbstractTumor removal remains the principal treatment modality in the management of solid tumors. The process of tumor removal may potentiate the resurgent growth of residual neoplastic tissue. Herein, we describe a novel murine model in which flank tumor cytoreduction is followed by accelerated local tumor recurrence. This model held for primary and recurrent tumors generated using a panel of human and murine (LS174T, DU145, SW480, SW640, and 3LL) cell lines and replicated accelerated tumor growth following excisional surgery. In investigating this further, epithelial cells were purified from LS174T primary and corresponding recurrent tumors for comparison. Baseline as well as tumor necrosis factor apoptosis-inducing ligand (TRAIL)-induced apoptosis were significantly reduced in recurrent tumor epithelia. Primary and recurrent tumor gene expression profiles were then compared. This identified an increase and reduction in the expression of p110gamma and p85alpha class Ia phosphoinositide 3-kinase (PI3K) subunits in recurrent tumor epithelia. These changes were further confirmed at the protein level. The targeting of PI3K ex vivo, using LY294002, restored sensitivity to TRAIL in recurrent tumor epithelia. In vivo, adjuvant LY294002 prolonged survival and significantly attenuated recurrent tumor growth by greatly enhancing apoptosis levels. Hence, PI3K plays a role in generating the antiapoptotic and chemoresistant phenotype associated with accelerated local tumor recurrence.
- Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas.
- Authors: Kim S, Kang J, Qiao J, Thomas RP, Evers BM, Chung DH
- Issue date: 2004 Apr
- Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
- Authors: Krystal GW, Sulanke G, Litz J
- Issue date: 2002 Sep
- The targeting of phosphoinositide-3 kinase attenuates pulmonary metastatic tumor growth following laparotomy.
- Authors: Coffey JC, Wang JH, Bouchier-Hayes D, Cotter TG, Redmond HP
- Issue date: 2006 Feb
- A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
- Authors: Martelli AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L, Ruggeri A, Conte R, Cocco L
- Issue date: 2003 Sep
- Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.
- Authors: Thakkar H, Chen X, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK
- Issue date: 2001 Oct 19